Literature DB >> 20665724

Mitochondria in the striatum of subjects with schizophrenia: relationship to treatment response.

Shahza M Somerville1, Adrienne C Lahti, Robert R Conley, Rosalinda C Roberts.   

Abstract

Schizophrenia (SZ) is a severe mental illness with neuropathology in many regions, including the striatum. The typical symptoms of this disease are psychosis (such as hallucinations and delusions), cognitive impairments, and the deficit syndrome. Not all patients respond to treatment and, in those who do, only psychotic symptoms are improved. Imaging studies support a biological distinction between treatment response and resistance, but postmortem examinations of this issue are rare. This study tests the hypotheses that abnormalities in mitochondria, the energy producing organelles in the cell, may correlate with treatment response. Postmortem striatal tissue was obtained from the Maryland Brain Collection. The density of mitochondria (in various neuropil compartments) and the number of mitochondria per synapse (all types of synapses combined) were tallied using electron microscopy and stereology in striatum from SZ subjects (rated treatment responsive or not) and normal controls. The number of mitochondria per synapse was significantly different among groups for both the caudate nucleus (P < 0.025) and putamen (P < 0.002). Compared to controls, treatment-responsive SZ subjects had a 37-43% decrease in the number of mitochondria per synapse in the caudate nucleus and putamen. In the putamen, treatment-responsive subjects also had decreases in this measure compared to treatment-resistant subjects (34%). Our results provide further support for a biological distinction between treatment response and treatment resistance in SZ. Because treatment responders have fewer mitochondria per synapse than controls, although the treatment-resistant subjects have similar results to that of controls, fewer mitochondria per synapse may be related to treatment response. 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20665724      PMCID: PMC4504676          DOI: 10.1002/syn.20838

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  80 in total

1.  Evidence for a mitochondrial oxidative phosphorylation defect in brains from patients with schizophrenia.

Authors:  I Maurer; S Zierz; H Möller
Journal:  Schizophr Res       Date:  2001-03-01       Impact factor: 4.939

2.  Axonal mitochondrial transport and potential are correlated.

Authors:  Kyle E Miller; Michael P Sheetz
Journal:  J Cell Sci       Date:  2004-05-18       Impact factor: 5.285

3.  Synaptic differences in the postmortem striatum of subjects with schizophrenia: a stereological ultrastructural analysis.

Authors:  Rosalinda C Roberts; Joy K Roche; Robert R Conley
Journal:  Synapse       Date:  2005-06-15       Impact factor: 2.562

Review 4.  Neurobiology of treatment-resistant schizophrenia: new insights and new models.

Authors:  L J Beerpoot; B K Lipska; D R Weinberger
Journal:  Eur Neuropsychopharmacol       Date:  1996       Impact factor: 4.600

5.  Inhibition of complex I by neuroleptics in normal human brain cortex parallels the extrapyramidal toxicity of neuroleptics.

Authors:  I Maurer; H J Möller
Journal:  Mol Cell Biochem       Date:  1997-09       Impact factor: 3.396

6.  Increase in caudate nuclei volumes of first-episode schizophrenic patients taking antipsychotic drugs.

Authors:  M H Chakos; J A Lieberman; R M Bilder; M Borenstein; G Lerner; B Bogerts; H Wu; B Kinon; M Ashtari
Journal:  Am J Psychiatry       Date:  1994-10       Impact factor: 18.112

Review 7.  Mitochondria, synaptic plasticity, and schizophrenia.

Authors:  Dorit Ben-Shachar; Daphna Laifenfeld
Journal:  Int Rev Neurobiol       Date:  2004       Impact factor: 3.230

Review 8.  Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence.

Authors:  P J Harrison; D R Weinberger
Journal:  Mol Psychiatry       Date:  2005-01       Impact factor: 15.992

9.  Ketamine activates psychosis and alters limbic blood flow in schizophrenia.

Authors:  A C Lahti; H H Holcomb; D R Medoff; C A Tamminga
Journal:  Neuroreport       Date:  1995-04-19       Impact factor: 1.837

10.  Ultrastructural abnormalities of astrocytes in the hippocampus in schizophrenia and duration of illness: a postortem morphometric study.

Authors:  Natalya S Kolomeets; Natalya Uranova
Journal:  World J Biol Psychiatry       Date:  2010-03       Impact factor: 4.132

View more
  14 in total

1.  Elevated Excitatory Input to the Nucleus Accumbens in Schizophrenia: A Postmortem Ultrastructural Study.

Authors:  Lesley A McCollum; Courtney K Walker; Joy K Roche; Rosalinda C Roberts
Journal:  Schizophr Bull       Date:  2015-03-27       Impact factor: 9.306

Review 2.  Postmortem studies on mitochondria in schizophrenia.

Authors:  Rosalinda C Roberts
Journal:  Schizophr Res       Date:  2017-02-09       Impact factor: 4.939

3.  Mitochondrial Complex I Deficiency in Schizophrenia and Bipolar Disorder and Medication Influence.

Authors:  Brandi L Rollins; Ling Morgan; Brooke E Hjelm; Adolfo Sequeira; Alan F Schatzberg; Jack D Barchas; Francis S Lee; Rick M Myers; Stanley J Watson; Huda Akil; Steven G Potkin; William E Bunney; Marquis P Vawter
Journal:  Mol Neuropsychiatry       Date:  2017-11-30

4.  Update on the neurobiology of schizophrenia: a role for extracellular microdomains.

Authors:  D Shan; S Yates; R C Roberts; R E McCullumsmith
Journal:  Minerva Psichiatr       Date:  2012-09-01

Review 5.  Molecular links between mitochondrial dysfunctions and schizophrenia.

Authors:  Cana Park; Sang Ki Park
Journal:  Mol Cells       Date:  2012-02-15       Impact factor: 5.034

6.  Decreased synaptic and mitochondrial density in the postmortem anterior cingulate cortex in schizophrenia.

Authors:  R C Roberts; K A Barksdale; J K Roche; A C Lahti
Journal:  Schizophr Res       Date:  2015-07-22       Impact factor: 4.939

7.  Metabolite measurements in the caudate nucleus, anterior cingulate cortex and hippocampus among patients with mitochondrial disorders: a case-control study using proton magnetic resonance spectroscopy.

Authors:  Rebecca E Anglin; Patricia I Rosebush; Michael D Noseworthy; Mark Tarnopolsky; Alexander M Weber; Noam Soreni; Michael F Mazurek
Journal:  CMAJ Open       Date:  2013-04-26

8.  Molecular hydrogen: an overview of its neurobiological effects and therapeutic potential for bipolar disorder and schizophrenia.

Authors:  Ahmad Ghanizadeh; Michael Berk
Journal:  Med Gas Res       Date:  2013-06-06

9.  Association of telomere length and mitochondrial DNA copy number with risperidone treatment response in first-episode antipsychotic-naïve schizophrenia.

Authors:  Zongchang Li; Maolin Hu; Xiaofen Zong; Ying He; Dong Wang; Lulin Dai; Min Dong; Jun Zhou; Hongbao Cao; Luxian Lv; Xiaogang Chen; Jinsong Tang
Journal:  Sci Rep       Date:  2015-12-18       Impact factor: 4.379

10.  Mitochondrial dysfunction in schizophrenia: With a focus on postmortem studies.

Authors:  Rosalinda C Roberts
Journal:  Mitochondrion       Date:  2020-11-20       Impact factor: 4.160

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.